AR058130A1 - Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer - Google Patents

Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer

Info

Publication number
AR058130A1
AR058130A1 ARP060104602A ARP060104602A AR058130A1 AR 058130 A1 AR058130 A1 AR 058130A1 AR P060104602 A ARP060104602 A AR P060104602A AR P060104602 A ARP060104602 A AR P060104602A AR 058130 A1 AR058130 A1 AR 058130A1
Authority
AR
Argentina
Prior art keywords
against cancer
cancer
therapy against
compositions
improved
Prior art date
Application number
ARP060104602A
Other languages
English (en)
Spanish (es)
Inventor
Mangesh M Kulkarni
Ajay K Grupta
Ambarish K Singh
Sarabjit Singh
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of AR058130A1 publication Critical patent/AR058130A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP060104602A 2005-10-21 2006-10-20 Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer AR058130A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1327MU2005 2005-10-21
IN1081MU2006 2006-07-10

Publications (1)

Publication Number Publication Date
AR058130A1 true AR058130A1 (es) 2008-01-23

Family

ID=38163340

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104602A AR058130A1 (es) 2005-10-21 2006-10-20 Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer

Country Status (13)

Country Link
US (1) US20100166872A1 (https=)
EP (1) EP1962906A4 (https=)
JP (1) JP2009512682A (https=)
AR (1) AR058130A1 (https=)
AU (1) AU2006324872B2 (https=)
BR (1) BRPI0617663A2 (https=)
CA (1) CA2626016A1 (https=)
CR (1) CR9989A (https=)
EA (1) EA015781B1 (https=)
IL (1) IL190882A0 (https=)
MA (1) MA29946B1 (https=)
RS (1) RS20080167A (https=)
WO (1) WO2007069272A2 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087678A2 (en) * 2007-12-24 2009-07-16 Sun Pharma Advanced Research Company Limited Nanodispersion
US8865223B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
US8871276B2 (en) 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
WO2009101614A1 (en) * 2008-02-11 2009-08-20 Technion Research & Development Foundation Ltd. Casein particles encapsulating therapeutically active agents and uses thereof
US8865222B2 (en) 2008-02-11 2014-10-21 Technion Research And Development Foundation Ltd. Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof
GB0818747D0 (en) 2008-10-13 2008-11-19 Univ Nottingham Biocompatible responsive materials
EP2266546A1 (en) 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
EP2442805A4 (en) 2009-06-19 2012-11-21 Sun Pharma Advanced Res Co Ltd NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME
WO2011017835A1 (en) * 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
IN2012DN02576A (https=) * 2009-09-21 2015-08-28 Jw Pharmaceutical Corportion
US10842770B2 (en) 2010-05-03 2020-11-24 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
CA2801309C (en) * 2010-06-01 2018-07-17 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
EP2645991B1 (en) 2010-12-02 2020-02-12 GreenMark Biomedical Inc. Aptamer bioconjugate drug delivery device
KR20140022904A (ko) 2011-04-20 2014-02-25 유니버시티 오브 시드니 치료방법 및 그에 사용가능한 제제
DK2701684T3 (en) 2011-04-28 2017-09-18 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
RS60093B1 (sr) 2013-09-16 2020-05-29 Astrazeneca Ab Terapeutske polimerne nanočestice i postupci njihove pripreme i primene
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
HUP1300646A2 (en) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN103739672B (zh) * 2013-12-31 2015-06-10 威特曼生物科技（南京）有限公司 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用
RU2591819C2 (ru) * 2014-03-03 2016-07-20 Закрытое акционерное общество "СКАЙ ЛТД" Способ получения фолликулярного белкового препарата и препарат, полученный данным способом
CN117899029A (zh) 2015-02-01 2024-04-19 希洛斯医药品股份有限公司 用于在患者中口服施用的含有砷的高表面积冻干组合物
EP3265063A4 (en) 2015-03-03 2018-11-07 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
US9895313B2 (en) 2015-03-03 2018-02-20 Cureport, Inc. Combination liposomal pharmaceutical formulations
CN106137969B (zh) 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
EP3615011A4 (en) * 2017-04-24 2021-01-06 ZY Therapeutics Inc. PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER
WO2019028457A2 (en) * 2017-08-04 2019-02-07 University Of Houston System FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE
WO2019191456A1 (en) 2018-03-28 2019-10-03 Greenmark Biomedical Inc. Phosphate crosslinked starch nanoparticle and dental treatments
AU2019312592B2 (en) 2018-07-31 2025-06-26 Microbion Corporation Bismuth-thiol compositions and methods for treating wounds
WO2020028558A1 (en) 2018-07-31 2020-02-06 Microbion Corporation Bismuth-thiol compositions and methods of use
FR3087650B1 (fr) * 2018-10-31 2021-01-29 Bio Even Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer
CN114767879A (zh) * 2022-06-02 2022-07-22 平顶山学院 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
WO1994026254A1 (en) * 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
PT1023050E (pt) * 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
HK1045646A1 (zh) * 1999-05-21 2002-12-06 Abraxis Bioscience, Llc 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
AU2458501A (en) * 2000-01-05 2001-07-16 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
KR20120068035A (ko) * 2002-12-09 2012-06-26 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법

Also Published As

Publication number Publication date
RS20080167A (sr) 2009-07-15
JP2009512682A (ja) 2009-03-26
CA2626016A1 (en) 2007-06-21
AU2006324872B2 (en) 2012-03-08
BRPI0617663A2 (pt) 2011-08-02
EA015781B1 (ru) 2011-12-30
EP1962906A4 (en) 2009-11-18
MA29946B1 (fr) 2008-11-03
WO2007069272A2 (en) 2007-06-21
US20100166872A1 (en) 2010-07-01
EA200801132A1 (ru) 2009-02-27
CR9989A (es) 2008-07-18
WO2007069272A3 (en) 2007-08-23
AU2006324872A1 (en) 2007-06-21
EP1962906A2 (en) 2008-09-03
IL190882A0 (en) 2008-11-03

Similar Documents

Publication Publication Date Title
AR058130A1 (es) Composiciones mejoradas de terapia contra el cancer, metodo para hacer dicha composicion mejorada contra el cancer, metodo para tratar a un mamifero con una terapia contra el cancer y metodo para reducir los efectos secundarios inducidos por la quimioterapia de una terapia contra el cancer
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
MX346861B (es) Metodos de tratamiento de carcinoma hepato celular.
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
CR20120528A (es) Métodos para tratar el cáncer
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
UY31215A1 (es) Compuestos de morfolino pirimidina, procesos para su preparacion, composiciones farmacéuticas conteniéndolos y su uso en terapia.
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
UY30559A1 (es) Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
MX2011011514A (es) Formulaciones de canabidiol y metodos para utilizarlas.
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
AR071003A1 (es) Farmaco contra cancer de higado
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0908194B8 (pt) Uso de uma anexina a5 recombinante, e stent de eluição de fármaco
CY1115245T1 (el) Φαρμακευτικη συνθεση που συνδυαζει διαφορους φλεβοτονικους και αγγειοπροστατευτικους παραγοντες για τη θεραπεια χρονιας φλεβικης ανεπαρκειας
CO6761366A2 (es) Composiciones farmacéuticas para el tratamiento de glioma maligno
CR20110586A (es) Combinación antitumoral que comprende cabazitaxel y capecitabina
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos

Legal Events

Date Code Title Description
FB Suspension of granting procedure